Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence

By sjmartinez • January 25, 2025

Krishnan S, Srivastava PK, Attaluri J, Nayeri R, Chatterjee D, Patel J, Nsair A, Budoff M, Nayeri A. Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence. J Cardiovasc Dev Dis. 2025 Jan 7;12(1):19. doi: 10.3390/jcdd12010019. PMID: 39852297; PMCID: PMC11766028.

Tags: Cardiology/Epi, GIP GLP-1 receptor agonist, Harbor UCLA, Hematology/Oncology, Metabolic syndrome, Obesity, Publications, semaglutide, tirzepatide, Veterans Administration, weight loss

Genetic and sex-specific regulation of mitochondrial function in gonadal and inguinal adipose tissue

Kaminska D, Pan C, Vergnes L, Ro A, Ulaganathan G, Lusis AJ. Genetic and sex-specific regulation of mitochondrial function in gonadal and inguinal adipose tissue.[...]

A call for transparency, improved reporting, and interpretation of trials using surrogate end points in cardiac electrophysiology

Tereshchenko LG, Manyara AM, Ciani O, Sodeke SO, Bradford CN, Santangeli P, Kapadia SR, Wazni O, Narayan SM, Chugh SS, Bilchick K, Huizar JF, Vaseghi[...]

Trends in Cardiovascular Mortality in Patients With Chronic Kidney Disease From 1999 to 2020: A Retrospective Study in the United States

Ahmad E, Ahmad S, Naeem A, Ahmed S, Shehzad M, Akram U, Ashraf H, Rehman OU, Ullah I, Ahmed R, Alraies C, Fonarow GC. Trends[...]